GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (STU:NOVA) » Definitions » Cyclically Adjusted PS Ratio

Novo Nordisk A/S (STU:NOVA) Cyclically Adjusted PS Ratio : 28.10 (As of May. 21, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Novo Nordisk A/S Cyclically Adjusted PS Ratio?

As of today (2024-05-21), Novo Nordisk A/S's current share price is €122.50. Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €4.36. Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is 28.10.

The historical rank and industry rank for Novo Nordisk A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

STU:NOVA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.17   Med: 11.73   Max: 29.45
Current: 28.07

During the past years, Novo Nordisk A/S's highest Cyclically Adjusted PS Ratio was 29.45. The lowest was 8.17. And the median was 11.73.

STU:NOVA's Cyclically Adjusted PS Ratio is ranked worse than
87.77% of 507 companies
in the Biotechnology industry
Industry Median: 5.55 vs STU:NOVA: 28.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Novo Nordisk A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was €1.960. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €4.36 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novo Nordisk A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Novo Nordisk A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Cyclically Adjusted PS Ratio Chart

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.28 10.42 16.05 17.24 22.72

Novo Nordisk A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.19 19.08 21.53 22.72 27.39

Competitive Comparison of Novo Nordisk A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Novo Nordisk A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Cyclically Adjusted PS Ratio falls into.



Novo Nordisk A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Novo Nordisk A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=122.50/4.36
=28.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novo Nordisk A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.96/118.4000*118.4000
=1.960

Current CPI (Mar. 2024) = 118.4000.

Novo Nordisk A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.550 99.700 0.653
201409 0.570 99.700 0.677
201412 0.635 99.400 0.756
201503 0.648 100.200 0.766
201506 0.702 100.300 0.829
201509 0.698 100.200 0.825
201512 0.759 99.800 0.900
201603 0.715 100.200 0.845
201606 0.726 100.600 0.854
201609 0.730 100.200 0.863
201612 0.790 100.300 0.933
201703 0.765 101.200 0.895
201706 0.784 101.200 0.917
201709 0.724 101.800 0.842
201712 0.764 101.300 0.893
201803 0.740 101.700 0.862
201806 0.757 102.300 0.876
201809 0.769 102.400 0.889
201812 0.828 102.100 0.960
201903 0.821 102.900 0.945
201906 0.843 102.900 0.970
201909 0.854 102.900 0.983
201912 0.918 102.900 1.056
202003 0.962 103.300 1.103
202006 0.858 103.200 0.984
202009 0.890 103.500 1.018
202012 0.929 103.400 1.064
202103 0.981 104.300 1.114
202106 0.963 105.000 1.086
202109 1.043 105.800 1.167
202112 1.124 106.600 1.248
202203 1.238 109.900 1.334
202206 1.218 113.600 1.269
202209 1.349 116.400 1.372
202212 1.429 115.900 1.460
202303 1.589 117.300 1.604
202306 1.620 116.400 1.648
202309 1.754 117.400 1.769
202312 1.975 116.700 2.004
202403 1.960 118.400 1.960

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novo Nordisk A/S  (STU:NOVA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Novo Nordisk A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (STU:NOVA) Business Description

Industry
Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.